Antitumor Effects of Vanillin Based Chalcone Analogues in Vitro

Abstract

Colorectal cancer (CRC) is the third most common malignancy worldwide. CRC represents 13% of all malignant tumors and it may be expected to overcome the mortality rate of patients with heart diseases in the near future (1, 2). Approximately, one half of the population in Western countries develops a colorectal tumor by the age of 70 (3, 4). However, this type of cancer is more frequent among younger population, due to obesity, bad nutritional habits, smoking and lack of physical activity (5). Colorectal cancer develops as a polyp or adenoma in the intestinal mucosa. Malignant transformation of benign changes depends on its size and histological presentation (1). In previous years, the survival rate of patients with metastatic colorectal cancer increased significantly due to the development and the application of new chemotherapy regimens (6). There are several types of cell deaths, of which two are the main types: apoptosis and necrosis. Apoptosis, a programmed cell death, is character

Chalcones and Gastrointestinal Cancers: Experimental Evidence

“…In various colon cancer cells, chalcone treatment leads to either the activation of the proapoptotic members of the Bcl-2 protein family (e.g., Bax and Bad) or the suppression of antiapoptotic proteins (e.g., Bcl-xL and Bcl-2), resulting in the release of several proapoptotic proteins (e.g., cytochrome and Smac/DIABLO) and the activation of initiator caspase 9 or execution caspases 3/7. Moreover, a decrease in MMP has also often been detected [ 26 , 27 , 31 , 40 , 41 ].…”

Anticancer Activity of Chalcones and Its Derivatives: Review and In Silico Studies

“…Vanillin-based chalcone analogues were discussed by Lukovic and collaborators (2020) [ 36 ]. The IC50 values observed in the HCT-116 cell models were equivalent to 6.85 ± 0.71 μg/mL for Compound 9 ( Figure 5 ) and 7.9 ± 1.37 μg/mL for Compound 10 ( Figure 5 ).…”